The collaboration supports the goal of PATH’s pneumococcal vaccine project to accelerate the development of new vaccines against pneumococcal disease that are effective and affordable for the developing world, which includes new pneumococcal conjugate vaccines (PCVs) specifically targeted to meet needs in low-resource countries. It further complements preclinical research already underway through a public-private partnership between PATH and the Centre for Biologics Evaluation and Research at the US Food and Drug Administration to improve the efficiency of a conjugation process for PCVs.
“Glythera is proud to partner with PATH,” says Anthony Baxter, Chairman of Glythera. “We look forward to working together to support the preclinical development of new technologies to produce vaccines that will make a real difference to people throughout the world.”
Glythera Ltd is a spin-out biotechnology company from the University of Bath, creating a new generation of biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide functionalisation and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics.
PATH is an international nonprofit organization that creates sustainable, culturally relevant solutions, enabling communities worldwide to break longstanding cycles of poor health. By collaborating with diverse public- and private-sector partners, PATH helps provide appropriate health technologies and vital strategies that change the way people think and act. PATH’s work improves global health and well-being. For more information, please visit www.path.org.
# # #
Glythera Limited is an emerging spin-out biotechnology company with core expertise in protein/peptide functionalisation and glycosylation technologies, imparting improved pharmacokinetic properties to biological therapeutics.